MPLT.US MapLight Therapeutics, Inc. Common Stock
- Market cap
- USD 403M
- P/E
- -
- P/B
- 1.16x
- ROE
- -69.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MPLT.US undervalued?
Graham numberThe Graham number of MapLight Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MapLight Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for MapLight Therapeutics, Inc. Common Stock yet.
MapLight Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits …
Full company profileMapLight Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MapLight Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | - | - | - | 0.00 | 0.00 |
| Gross Profit | -574K | -556K | -701K | -578K | -618K |
| Operating Income | -31.2M | -57.3M | -82.9M | -169M | -256M |
| EBITDA | -29.4M | -55.2M | -76.9M | -161M | -248M |
| Net Income | -30.0M | -55.7M | -77.6M | -161M | -242M |
| EPS | -0.72 | -1.34 | -1.87 | -3.66 | -5.32 |
| Balance Sheet | |||||
| Total Assets | 39.4M | 91.4M | 137M | 480M | 368M |
| Total Liabilities | 18.5M | 20.1M | 21.7M | 21.1M | 20.0M |
| Shareholders' Equity | 20.9M | 71.3M | 115M | 458M | 348M |
| Cash & Short-term Investments | 27.7M | 79.8M | 109M | 305M | 305M |
| Total Debt | 6.27M | 5.92M | 6.58M | 5.80M | 1.99M |
| Cash Flow | |||||
| Operating Cash Flow | -26.6M | -52.0M | -78.8M | -138M | -192M |
| Capital Expenditure | 746K | 462K | 770K | 473K | 92.0K |
| Free Cash Flow | -27.3M | -52.5M | -79.6M | -139M | -192M |
| Ratios | |||||
| ROE | -143.8% | -78.2% | -67.3% | -35.2% | -69.4% |
| ROA | -76.2% | -60.9% | -56.7% | -33.6% | -65.6% |
| Debt to Equity | 0.30x | 0.08x | 0.06x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
MapLight Therapeutics, Inc. Common Stock dividends
MapLight Therapeutics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns MapLight Therapeutics, Inc. Common Stock
- Insiders 52.39%
- Institutions 47.61%
- Public & others 0.00%
- Shares outstanding 52.8M
- Free float 15.8M
Top funds holding MPLT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Value | 493K | 0.89% | 0.00% | Sep 2026 |
| American Funds SMALLCAP World A | 404K | 0.73% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 314K | 0.57% | 0.00% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 203K | 0.37% | 0.00% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 191K | 0.34% | +0.02% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 172K | 0.31% | -68.84% | Sep 2026 |
| AXA Framlington Health Fund - R Income | 171K | 0.31% | 0.00% | Sep 2026 |
| Fidelity Series Small Cap Core | 138K | 0.25% | 0.00% | Aug 2026 |
| Fidelity Stock Selector Small Cap | 116K | 0.21% | -71.40% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 112K | 0.20% | +94.45% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 106K | 0.19% | -0.38% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 91.3K | 0.16% | +0.21% | Oct 2026 |
| Fidelity Extended Market Index | 85.9K | 0.15% | -7.44% | Sep 2026 |
| RIM Global Bioscience EUR | 75.5K | 0.14% | +268.65% | Jul 2026 |
| Vanguard Russell 2000 ETF | 75.0K | 0.13% | +25.54% | Sep 2026 |
| Fidelity Series Small Cap Opps | 68.6K | 0.12% | -73.95% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 63.2K | 0.11% | +0.27% | Oct 2026 |
| BlackRock Health Sciences Opps Inv A | 50.3K | 0.09% | 0.00% | Sep 2026 |
| Northwestern Mutual Ser Small Cap Value | 42.9K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 39.1K | 0.07% | -0.05% | Sep 2026 |
Top institutions holding MPLT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Novo A/S | 3.69M | 6.63% | 0.00% | Jun 2026 |
| FCPM III SERVICES BV | 3.23M | 5.81% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.78M | 5.01% | -0.72% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.95M | 3.51% | -2.33% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.42M | 2.56% | +1,162.50% | Jun 2026 |
| BlackRock Inc | 1.03M | 1.84% | -23.48% | Jun 2026 |
| Nan Fung Group Holdings Ltd | 971K | 1.75% | 0.00% | Jun 2026 |
| 5AM Venture Management, LLC | 950K | 1.71% | 0.00% | Jun 2026 |
| Sanofi | 912K | 1.64% | 0.00% | Sep 2026 |
| State Street Corp | 852K | 1.53% | +151.29% | Jun 2026 |
| FMR Inc | 824K | 1.48% | +302.71% | Jun 2026 |
| Vanguard Capital Management, LLC | 784K | 1.41% | +8.94% | Jun 2026 |
| Blue Owl Capital Holdings LP | 730K | 1.31% | -27.44% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 686K | 1.23% | 0.00% | Jun 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 611K | 1.10% | 0.00% | Sep 2026 |
| Velan Capital Investment Management LP | 493K | 0.89% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 450K | 0.81% | 0.00% | Jun 2026 |
| Capital World Investors | 416K | 0.75% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 402K | 0.72% | -16.45% | Jun 2026 |
| Baker Bros Advisors LP | 365K | 0.66% | 0.00% | Jun 2026 |
MapLight Therapeutics, Inc. Common Stock company profile
- Company name
- MapLight Therapeutics, Inc. Common Stock
- Ticker
- MPLT.US
- Exchange
- USA Stocks
- Listed since
- Oct 27, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 133
- Fiscal year end
- December
- Address
- 800 Chesapeake Drive, Redwood City, CA, United States, 94063
- Phone
- 617 984 6300
- Website
- maplightrx.com
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
MapLight Therapeutics, Inc. Common Stock management
9- Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D.Founder, President, CEO & Director · born 1968
- Dr. Robert C. Malenka M.D., Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1955
- Dr. Erin Pennock Foff M.D., Ph.D.Chief Medical Officer · born 1977
- Dr. Karoly Nikolich Ph.D.Founder & Member of Advisory Board · born 1948
- Dr. Karl Deisseroth M.D., Ph.D.Co-Founder & Member of Scientific Advisory Board
- Mr. Jonathan Gillis CPAChief Admin & Acc Officer, PAO, Interim CFO & PFO · born 1981
- Dr. James Woodruff Lillie Ph.D.Chief Scientific Officer · born 1956
- Mr. Kristopher L. Hanson J.D.General Counsel & Secretary · born 1972
- Dr. Anatol Kreitzer Ph.D.Chief Discovery Officer · born 1975